Psychiatrist
Dr. Bradley is an Assistant Professor of Psychiatry at UCSF and Associate Director of the Translational Psychedelic Research program. She also serves as lead psychiatrist for the Parkinson’s Disease Research, Education, and Clinical Center at the San Francisco VA. Her research focuses on clinical trials of psychoactive compounds like psilocybin to treat neuropsychiatric conditions, particularly depression in Parkinson’s disease. She led the first pilot study of psilocybin in Parkinson’s patients and is now overseeing a larger multi-site trial.
Publications
Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.
JAMA psychiatry
A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.
Psychiatry research
A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?
Psychedelic medicine (New Rochelle, N.Y.)
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Psychopharmacology
Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.
Psychopharmacology
Quantifying abnormal emotion processing: A novel computational assessment method and application in schizophrenia.
Psychiatry research
A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?.
Psychedelic Medicine
Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice.
Psychedelic medicine (New Rochelle, N.Y.)
Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies.
Journal of Affective Disorders Reports
Preliminary evidence that oxytocin does not improve mentalizing in women with schizophrenia.
Hormones and behavior
Oxytocin increases eye gaze in schizophrenia.
Schizophrenia research
Victory is its own reward: oxytocin increases costly competitive behavior in schizophrenia.
Psychological medicine
Oxytocin does not improve working memory in schizophrenia.
Schizophrenia research
S184. Oxytocin Increases Gaze to the Eyes in Schizophrenia.
Biological Psychiatry
S243. Heightened Effect of Unfairness and no Effect of Oxytocin on Ultimatum Game Behavior in Schizophrenia.
Biological Psychiatry
Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.
Neuroscience and biobehavioral reviews
1009 Oxytocin Enhances Overbidding in Multiplayer Auctions.
Biological Psychiatry
Postpartum depression screening in the pediatric emergency department.
Pediatric emergency care